{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:38:21Z","timestamp":1791049101218,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To determine the safety, dose\u2010limiting toxicity and maximum tolerated dose (MTD) of the novel hydroxamate histone deacetylase inhibitor belinostat (PXD101) in patients with advanced hematological neoplasms.<\/jats:p><jats:p><jats:bold>Patients and methods:\u2002<\/jats:bold> Sequential dose\u2010escalating cohorts of three to six patients with hematological malignancies received belinostat administered as a 30\u2010min i.v. infusion on days 1\u20135 of a 21\u2010d cycle. Experience from a parallel dose\u2010finding study in patients with solid tumors influenced the selection of the final dose.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Sixteen patients received belinostat at one of three dose levels: 600\u2003mg\/m<jats:sup>2<\/jats:sup>\/d (three patients), 900\u2003mg\/m<jats:sup>2<\/jats:sup>\/d (three patients) and 1000\u2003mg\/m<jats:sup>2<\/jats:sup>\/d (10 patients), the dose determined to be the MTD in a phase I solid tumor study [Steele <jats:italic>et\u00a0al<\/jats:italic>. (2008) <jats:italic>Clin Cancer Res<\/jats:italic>, <jats:bold>14,<\/jats:bold> 804\u201310].<\/jats:p><jats:p>The most common treatment\u2010related adverse events (all grades) were nausea (50%), vomiting (31%), fatigue (31%) and flushing (31%). No grade 3 or 4 hematological toxicity compared with baseline occurred except one case of grade 3 lymphopenia. There were two related grade 4 adverse events of renal failure observed. Both events occurred in patients with multiple myeloma and had similar characteristics, i.e. an acute episode of decrease in renal function (pre\u2010existing nephropathy in one patient), with a metabolic profile and decrease in tumor burden consistent with tumor lysis syndrome. No other related grade 4 events were noted. The only related grade 3 events noticed in more than one patient were fatigue and neurological symptoms (one patient had status epilepticus in association with uremia and one patient had paresthesia), all other related grade 3 events occurred in single patients. No cardiac events were noted.<\/jats:p><jats:p>No complete or partial remissions were noted in these heavily pre\u2010treated (median of four prior regimens) patients. However, five patients, including two patients with diffuse large\u2010cell lymphoma [including one patient with transformed chronic myelomcytic leukaemia (CLL)], two patients with CLL and one patient with multiple myeloma, achieved disease stabilization in of two to nine treatment cycles.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Intravenous belinostat at 600, 900 and 1000\u2003mg\/m<jats:sup>2<\/jats:sup>\/d is well tolerated by patients with hematological malignancies. The study was carried out in parallel to a similar dose\u2010finding study in patients with solid tumors, in which the MTD was determined to be 1000\u2003mg\/m<jats:sup>2<\/jats:sup>\/d days 1\u20135 in a 21\u2010d cycle. This dose can also be recommended for phase II studies in patients with hematological neoplasms.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01102.x","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T05:56:49Z","timestamp":1211954209000},"page":"170-176","source":"Crossref","is-referenced-by-count":150,"title":["A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia"],"prefix":"10.1111","volume":"81","author":[{"given":"Peter","family":"Gimsing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene M.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib Jarle","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chean Eng","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buhl\u2010Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,8,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1210"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701770104"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1018"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536759100"},{"key":"e_1_2_6_7_2","first-page":"721","article-title":"Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101","volume":"2","author":"Plumb JA","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3337.3337","article-title":"Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical studies and in a phase I study in patients with advanced hematological tumors","volume":"106","author":"Gimsing P","year":"2005","journal-title":"Blood"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1786"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_6_12_2","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly WK","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_13_2","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176) in patients with refractory neoplasms","volume":"8","author":"Sandor V","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh116"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.8.1205"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.064"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb00190.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115629"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116920"},{"key":"e_1_2_6_20_2","first-page":"810","article-title":"Biochemical interaction between Tamm\u2010Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy","volume":"73","author":"Huang ZQ","year":"1995","journal-title":"Lab Invest"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3483.3483","article-title":"Effects of a novel histone deacetylase inhibitor, PXD101, when used as monotherapy or in combination with bortezomib on tumor growth in mouse models of human multiple myeloma","volume":"108","author":"Campbell RA","year":"2006","journal-title":"Blood"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702294104"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9679"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V108.11.3583.3583","article-title":"A phase II study of PXD101 in advanced multiple myeloma","volume":"108","author":"Sullivan D","year":"2006","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01102.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01102.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T01:45:01Z","timestamp":1696988701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01102.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01102.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01102.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,7]]}}}